For Investors
A new approach to a growing bunion-care market.
HyperFlex® Medical is advancing a new category in bunion correction: a bone-preserving system designed to correct alignment without osteotomy or fusion, where clinically appropriate. FDA 510(k)-cleared and supported by issued patents, HyperFlex® is positioned for focused commercial adoption in orthopedic and podiatric markets.
Market Opportunity
A large market with meaningful unmet need.
Bunions affect an estimated 65 million Americans, while only a fraction seek treatment or proceed to surgery. Current procedural volume represents a small portion of the broader population affected by bunion deformity — creating a meaningful opportunity for innovation in care pathways and treatment options.
65M
Americans Affected
Estimated population living with bunion deformity.
6.3M
Seek Treatment
Patients who actively pursue care each year.
2.1M
Surgical Candidates
Patients for whom surgery may be appropriate.
430K
Current Procedures
Annual surgical volume in the U.S. today.
Market figures are directional and provided for context only.
Treatment Gap
Current options leave room for a less structurally disruptive approach.
Traditional bunion correction often involves cutting or fusing bone. Even newer minimally invasive approaches may still involve osteotomy. HyperFlex® was developed around a different principle: Preserve First — supporting alignment correction while preserving native bone structure and future surgical options where clinically appropriate.
Traditional Surgery
Often involves osteotomy or fusion, which changes native bone structure.
Minimally Invasive
Newer techniques may reduce incision size, but osteotomy often still applies.
HyperFlex® Approach
Designed to support correction while preserving native bone and future options.
The HyperFlex® Difference
Designed to correct without bone cuts or fusion.
HyperFlex® is built around a soft-tissue, load-bearing construct that supports bunion correction while preserving native bone structure and joint integrity where clinically appropriate.
Bone-Preserving Correction
Designed to support alignment correction without osteotomy or fusion where clinically appropriate.
No Osteotomy or Fusion
A correction pathway that avoids bone cuts and joint fusion, where clinically appropriate.
Soft-Tissue Construct
Uses a soft-tissue, load-bearing construct to support correction.
Preserves Future Options
Designed to keep traditional surgical pathways available if additional care is ever needed.
Validation & Defensibility
Built with regulatory, engineering, and IP discipline.
HyperFlex® has established a defensible foundation across regulatory clearance, bench testing, patent protection, and clinical advisory — each element reinforcing the system’s credibility for commercial adoption.
FDA 510(k) Cleared
Regulatory clearance supporting U.S. commercial activity across orthopedic and podiatric settings.
Bench Testing
Mechanical bench testing supports the system’s design rationale and informs product development decisions.
Issued Patents
Three issued U.S. patents and three issued EU patents, with additional intellectual property activity underway.
Clinical Advisors
Experienced orthopedic and podiatric surgeons guide responsible product development and procedural refinement.
Commercial Pathway
Focused commercialization in specialty markets.
HyperFlex® is pursuing adoption through targeted orthopedic and podiatric channels, with a focus on surgeon education, specialty distribution, clinical evaluation, and value-analysis support.
Specialty Focus
Targeted engagement with orthopedic and podiatric practices.
Surgeon Education
Training and clinical evaluation support for adopting surgeons.
Scalable Distribution
Specialty distribution and value-analysis support for focused market expansion.
Investment Thesis
Why HyperFlex® Medical
HyperFlex® Medical combines a large underserved market, differentiated bone-preserving technology, regulatory and IP foundation, and an experienced team — creating a focused opportunity in an established orthopedic category.
Large Underpenetrated Market
Bunions affect a broad population, while current surgical volumes represent a small portion of those affected — highlighting a meaningful opportunity to expand treatment options.
Differentiated Technology
Bone-preserving correction designed without cutting or fusion, addressing a meaningful gap in the existing treatment landscape.
Regulatory & IP Foundation
FDA 510(k) clearance and issued U.S. and EU patent protection provide a defensible foundation for commercial activity.
Experienced Team
Leadership, board members, and surgical advisors bring medical-device, foot-and-ankle, and commercial expertise to the organization.
Get in Touch
Interested in learning more?
Connect with HyperFlex® Medical to discuss the company, its technology, the market opportunity, or potential partnership and distribution strategies. We welcome conversations with investors, strategic partners, and medical-device stakeholders.
“`